Trial Profile
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Feb 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Rintodestrant (Primary) ; Fulvestrant
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors G1 Therapeutics
- 03 Feb 2023 Results from sub study investigating [18F]fluorodeoxyglucose ([18F]FDG) and [18F]FES PET/CT imaging for response prediction and monitoring of drug activity in patients Undergoing Treatment with Rintodestrant, published in the Clinical Cancer Research
- 14 Dec 2022 Status changed from active, no longer recruiting to completed.
- 11 Aug 2022 Planned End Date changed from 1 Mar 2024 to 30 Sep 2022.